For research use only. Not for therapeutic Use.
Iproplatin is a synthetic second-generation platinum-containing compound related to cisplatin. Iproplatin binds to and forms DNA crosslinks and platinum-DNA adducts, resulting in DNA replication failure and cell death. Although less prone to glutathione inactivation compared to cisplatin, resistance to this agent has been observed in vitro due to repair of platination damage by tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Catalog Number | I007352 |
| CAS Number | 62928-11-4 |
| Synonyms | CHIP; Code name: JM9; JM-9; JM 9.;cis,trans,cis-Dichlorodihydroxobis(isopropylamine)platinum |
| Molecular Formula | C6H22Cl2N2O2Pt |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 3 years -20C powder |
| IUPAC Name | dichloroplatinum;propan-2-amine;dihydrate |
| InChI | InChI=1S/2C3H9N.2ClH.2H2O.Pt/c2*1-3(2)4;;;;;/h2*3H,4H2,1-2H3;2*1H;2*1H2;/q;;;;;;+2/p-2 |
| InChIKey | DQSHQBDTHGZRSN-UHFFFAOYSA-L |
| SMILES | CC(C)N.CC(C)N.O.O.Cl[Pt]Cl |
| Reference | </br>1:Insight into the reactive form of the anticancer agent iproplatin. Volckova E, Weaver E, Bose RN.Eur J Med Chem. 2008 May;43(5):1081-4. Epub 2007 Jul 10. PMID: 17707553 </br>2:The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma. Pawinski A, Crowther D, Keizer HJ, Voûte PA, Somers R, van Glabbeke M, Lentz MA, van Oosterom AT.Eur J Cancer. 1999 Jan;35(1):163-4. No abstract available. PMID: 10211107 </br>3:Interaction of sodium chloroplatinate and iproplatin with metallothionein in vivo. Zhong W, Zhang Q, Yan Y, Yue S, Zhang B, Tang W.J Inorg Biochem. 1997 May 15;66(3):159-64. PMID: 9130391 </br>4:Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line. Pendyala L, Perez R, Weinstein A, Zdanowicz J, Creaven PJ.Cancer Chemother Pharmacol. 1997;40(1):38-44. PMID: 9137527 </br>5:Proton NMR observation of the antineoplastic agent Iproplatin in vivo by selective multiple quantum coherence transfer (Sel-MQC). He Q, Bhujwalla ZM, Maxwell RJ, Griffiths JR, Glickson JD.Magn Reson Med. 1995 Mar;33(3):414-6. PMID: 7760709 </br>6:Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. Castleberry RP, Cantor AB, Green AA, Joshi V, Berkow RL, Buchanan GR, Leventhal B, Mahoney DH, Smith EI, Hayes FA.J Clin Oncol. 1994 Aug;12(8):1616-20. PMID: 8040674 </br>7:Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center. Vermorken JB, Gundersen S, Clavel M, Smyth JF, Dodion P, Renard J, Kaye SB.Ann Oncol. 1993 Apr;4(4):303-6. PMID: 8518220 </br>8:Phase II trial of iproplatin in advanced squamous cell carcinoma of the head and neck, oesophagus and lung. Cappelaere P, Guiochet N, Bastit P, Favre R, Vanderburg M, Goupil A, Chauvergne J, Thomas D, Van Glabbeke M, Armand JP.Eur J Cancer. 1993;29A(8):1216. No abstract available. PMID: 8518037 </br>9:Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Hubbard KP, Pazdur R, Ajani JA, Braud E, Blaustein A, King M, Llenado-Lee M, Winn R, Levin B, Abbruzzese JL.Am J Clin Oncol. 1992 Dec;15(6):524-7. PMID: 1449117 </br>10:Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. Murphy BA, Motzer RJ, Bosl GJ.Invest New Drugs. 1992 Nov;10(4):327-30. PMID: 1336770 |
